Provided by Tiger Trade Technology Pte. Ltd.

Capital Research Global Investors

2,910.58
+31.521.09%
Number of Gainers:62
Number of Losers:33
Number of Flat:- -
PE:- -
High:2,924.13
Open:2,879.17
Low:2,879.17
Close:2,879.06
Volume:634.62M
Turnover:132.66B
Market Cap:33.29T
Float Cap:31.66T

Loading ...

Peloton Interactive Inc : UBS Cuts Target Price to $10 from $11

THOMSON REUTERS
·
Sep 08

ADP, Amazon Web Services announce expanded partnership

TIPRANKS
·
Sep 08

In Australia's Shale Patch, Americans Bring Money, Tech and Lessons Learned

Reuters
·
Sep 08

ADP Expands Strategic Partnership with AWS to Accelerate AI-Powered HCM Innovation

Reuters
·
Sep 08

Malaysia's Maybank Raises $700 Million in Dual-Tranche Dollar Bond Sale, Term Sheet Shows

Reuters
·
Sep 08

Qualcomm Stock Jumps 8% Thanks to Deal with Amazon

Dow Jones
·
Sep 08

Autodesk, Inc.: Files for Two-Part Notes Offering, Size not Disclosed - SEC Filing

THOMSON REUTERS
·
Sep 08

Qualcomm to issue warrant to Amazon.com for up to 25M shares

TIPRANKS
·
Sep 08

Navan, Engine announce strategic technology partnership

TIPRANKS
·
Sep 08

Amazon and AT&T Team up to Challenge SpaceX's Satellite Dominance

Dow Jones
·
Sep 08

Why Micron Stock is Popping on Fresh Memory-Chip Price Data

Dow Jones
·
Sep 08

Accenture, Google Cloud launch Accenture Gemini Enterprise Business Group

TIPRANKS
·
Sep 08

Qualcomm Shares up 10.1% Premarket After Co, Amazon to Develop Custom Chips for AI Data Centers

THOMSON REUTERS
·
Sep 08

AstraZeneca announces results from Phase III trial of IMFINZI, tarlatamab

TIPRANKS
·
Sep 08

Qualcomm announces multi-generation collaboration with Amazon.com

TIPRANKS
·
Sep 08

Qualcomm Partners with Amazon on Multi-Generation Custom Chips for AWS AI Data Centers

Reuters
·
Sep 08

Amgen - Phase 3 Dellphi-305 Study Delivers Significant Overall Survival Benefit Versus Durvalumab Alone

THOMSON REUTERS
·
Sep 08

Imdelltra® in Combination with Imfinzi® Demonstrated Landmark Improvement in Overall Survival in First-Line Extensive Stage Small Cell Lung Cancer

THOMSON REUTERS
·
Sep 08

Amgen - Study Meets Secondary Endpoints for Progression-Free Survival and Objective Response Rate

THOMSON REUTERS
·
Sep 08

Amgen - no New or Unexpected Safety Signals Identified in Dellphi-305 Study

THOMSON REUTERS
·
Sep 08